Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients...
-
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1 Results reinforce...
-
The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic...
-
Nello studio pivotale Vivacity-MG3 e nella sua fase di estensione in aperto, nuovi e convincenti risultati dimostrano una riduzione costante degli anticorpi di tipo immunoglobuline G e un...
-
Die subkutane (SC) Verabreichung von amivantamab bietet den Patienten mehr Komfort, da sich die Verabreichungszeit von Stunden auf Minuten verkĂĽrzt und die Zahl der infusionsbedingten Reaktionen im...
-
Cet approbation renforce l’utilisation du daratumumab en traitement fondamental chez les patients atteints d’un myélome multiple nouvellement diagnostiqué, en faisant ainsi le seul anticorps anti-CD38...
-
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...
-
New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension...
-
Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in infusion-related reactions compared to the IV...
-
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myeloma and the only anti-CD38 antibody for all patient types in this setting Phase 3 CEPHEUS study shows...